System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 40089635 DOI: 10.1038/s41416-025-02971-0

ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer.

Br J Cancer 132(9):814-821

Authors: Adrien Grancher, Ludivine Beaussire-Trouvay, Virginie Vernon, Marie Dutherage, Valérie Blondin, Caroline Elie, Karine Bouhier-Leporrier, Marie-Pierre Galais, Tifenn Clabaut, Anne-Laure Bignon, Aurélie Parzy, Alice Gangloff, Lilian Schwarz, Emilie Lévêque, Jean-Christophe Sabourin, Pierre Michel, Nasrin Vasseur, David Sefrioui, André Gilibert, Frédéric Di Fiore

Affiliations

  • Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Normandy Centre for Genomic and Personalized Medicine and Department of Hepato-gastroenterology and Digestive Oncology, Rouen University Hospital, Rouen, France.
  • Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, Rouen, France.
  • CHI Elbeuf, Department of Hepatogastroenterology, Elbeuf, France.
  • Department of Hepatogastroenterology, Caen University Hospital, Caen, France.
  • Department of Hepatogastroenterology, Francois Baclesse Centre, Caen, France.
  • Department of Biostatistics, Rouen University Hospital, Rouen, France.
  • Clinique du Cèdre, Bois-Guillaume, France.
  • Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
  • Clinical Research Unit, Centre Henri Becquerel, Rouen, France.
  • Department of Anatomopathology, Rouen University Hospital, Rouen, France.
  • Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Normandy Centre for Genomic and Personalized Medicine and Department of Hepato-gastroenterology and Digestive Oncology, Rouen University Hospital, Rouen, France.

Abstract

BACKGROUND

Circulating tumor DNA variations (∆ctDNA) were reported to be associated with treatment efficacy in metastatic colorectal cancer (mCRC). The present study evaluated ∆ctDNA according to first-line treatment intensity.

METHODS

Patients from two prospective ctDNA collections were divided into Group ≤ 2 drugs and Group ≥ 3 drugs. ∆ctDNA were analysed from baseline to cycle 3 or 4 (C 3-4) according to three predefined subgroups: ∆ctDNA ≥ 80% _ undetectable, ∆ctDNA ≥ 80% _ detectable, and ∆ctDNA < 80%. Impact of ∆ctDNA on progression-free survival (PFS) and overall survival (OS) were analysed.

RESULTS

Pretreatment ctDNA was detected in 129/152 (84.9%) of patients. A ∆ctDNA ≥ 80% _undetectable was more frequent in Group ≥ 3 than ≤ 2 drugs (respectively 51.5% vs. 32.7%, p = 0.015). Patients with ∆ctDNA ≥ 80% _undetectable had longer survival than other ∆ctDNA subgroups, in Group ≥ 3 drugs (mPFS 11.5 vs 7.8 vs 6.3 months, p = 0.02: mOS 30.2 vs 18.1 vs 16.4 month, p = 0.04) and in Group ≤ 2 drugs (mPFS 8.4 vs 6.0 vs 5.3 months, p = 0.05; mOS 29.6 vs 14.6 vs 14.6 months, p = 0.007).

DISCUSSION

Early ∆ctDNA are associated to treatment intensity in first line mCRC with a significant impact on prognosis.

MeSH

Pharmaceutical Preparations, Neoplasms, Therapeutics, Colorectal Neoplasms

Cited by